News
Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing.
Osteopore is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgery use.
Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX rebounds as soft CPI bolsters August rate cut hopes; OSX and TLM lead today’s winners
News
ASX Small Caps Lunch Wrap: Osteopore’s gone 1000% bananas, and here’s the rest of the news.
News
Top 10 at 11: Big tick for Aussie health tech in Asia, and some solid silver and graphite news
News
Market Highlights: Trump’s IPO stock jumps on debut; and 5 ASX small caps to watch today
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Caps and IPO Weekly Wrap: Mining stocks just hit their lowest point since November 2022
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Osteopore to find new China markets after partnering with Temasek-linked firm
Health & Biotech
ASX Health Stocks: BOD to acquire Aqua Phase on positive data; Bionomics set to delist
News
Top 10 at 10: Who’s planning to tap a $6bn Chinese market?
News
Market Highlights: Wall Street rises ahead of Big Tech earnings; Goldman says more upside for stocks in 2023
Health & Biotech
ASX Health Stocks: Successful toxicology tests pave the way for PYC’s Phase 2 clinical trial
News
In Case You Missed It: Lithium, rare earth and pharma players do the heavy lifting
News
Market Highlights: New banking crisis as First Republic seeks a lifeline; and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Osteopore licenses its bone regeneration technology; Kazia resolves problem with Nasdaq
News